JP2014523252A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523252A5
JP2014523252A5 JP2014520633A JP2014520633A JP2014523252A5 JP 2014523252 A5 JP2014523252 A5 JP 2014523252A5 JP 2014520633 A JP2014520633 A JP 2014520633A JP 2014520633 A JP2014520633 A JP 2014520633A JP 2014523252 A5 JP2014523252 A5 JP 2014523252A5
Authority
JP
Japan
Prior art keywords
dendritic cell
functionally equivalent
tolerogenic dendritic
equivalent variant
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014520633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523252A (ja
JP6290078B2 (ja
Filing date
Publication date
Priority claimed from EP11382240A external-priority patent/EP2557089A2/en
Application filed filed Critical
Publication of JP2014523252A publication Critical patent/JP2014523252A/ja
Publication of JP2014523252A5 publication Critical patent/JP2014523252A5/ja
Application granted granted Critical
Publication of JP6290078B2 publication Critical patent/JP6290078B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014520633A 2011-07-15 2012-07-16 免疫調節のための組成物および方法 Active JP6290078B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382240A EP2557089A2 (en) 2011-07-15 2011-07-15 Compositions and methods for immunomodulation
EP11382240.7 2011-07-15
PCT/EP2012/063932 WO2013010998A2 (en) 2011-07-15 2012-07-16 Compositions and methods for immunomodulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017130703A Division JP2017221196A (ja) 2011-07-15 2017-07-03 免疫調節のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014523252A JP2014523252A (ja) 2014-09-11
JP2014523252A5 true JP2014523252A5 (https=) 2015-09-03
JP6290078B2 JP6290078B2 (ja) 2018-03-07

Family

ID=45563648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520633A Active JP6290078B2 (ja) 2011-07-15 2012-07-16 免疫調節のための組成物および方法
JP2017130703A Pending JP2017221196A (ja) 2011-07-15 2017-07-03 免疫調節のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017130703A Pending JP2017221196A (ja) 2011-07-15 2017-07-03 免疫調節のための組成物および方法

Country Status (9)

Country Link
US (1) US10106589B2 (https=)
EP (3) EP2557089A2 (https=)
JP (2) JP6290078B2 (https=)
AU (1) AU2012285852B2 (https=)
CA (1) CA2841994C (https=)
DK (1) DK2731963T3 (https=)
ES (1) ES2581278T3 (https=)
PL (1) PL2731963T3 (https=)
WO (1) WO2013010998A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
AU2014236778B2 (en) * 2013-03-14 2019-01-03 Baxalta GmbH Factor H for transplantation
CA2929310C (en) 2013-11-18 2024-07-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MICROSPHERE-BASED ADMINISTRATION AND EX VIVO MANIPULATION OF DENDRITE CELLS FOR AUTOIMMUNE THERAPIES
FR3018819A1 (fr) * 2014-03-19 2015-09-25 Univ Bourgogne Traitement de la reponse inflammatoire et dysimmunitaire
EP3384923A1 (en) 2017-04-06 2018-10-10 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) C4bp-based compounds for treating immunological diseases
EP3808763A1 (en) * 2019-10-17 2021-04-21 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for immunomodulation
WO2025172510A1 (en) 2024-02-15 2025-08-21 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Compounds for treating diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
CA2049964A1 (en) * 1990-01-26 1991-07-27 Biogen, Inc. C4 binding protein fusion proteins
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
CA2230195A1 (en) 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
CN100455600C (zh) * 2002-08-14 2009-01-28 阿维迪斯公司 包含支架,佐剂和抗原的异源多聚体化合物及其用途
WO2004020639A2 (en) * 2002-08-14 2004-03-11 Avidis Sa Production of multimeric fusion proteins using a c4bp scaffold
WO2005051414A1 (en) * 2003-11-26 2005-06-09 Avidis Sa Use of c4bp core region as a cd40 agonist
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
EP1790358A1 (en) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Protein constructs designed for targeting and lysis of cells
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US8840868B2 (en) * 2009-02-04 2014-09-23 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation

Similar Documents

Publication Publication Date Title
JP2014523252A5 (https=)
Li et al. M2 macrophage‐derived sEV regulate pro‐inflammatory CCR2+ macrophage subpopulations to favor post‐AMI cardiac repair
Xie et al. Immunoregulatory effects of stem cell-derived extracellular vesicles on immune cells
Balbi et al. First characterization of human amniotic fluid stem cell extracellular vesicles as a powerful paracrine tool endowed with regenerative potential
D’Alessio et al. Reparative T lymphocytes in organ injury
Yang et al. The roles of noncardiomyocytes in cardiac remodeling
CN110402146A (zh) 间充质干细胞群、其产物及其用途
JP2015529457A5 (https=)
CN107849536A (zh) 用于得到调节性t细胞的方法及其用途
WO2009134429A2 (en) Methods and compositions for modulating immunological tolerance
JP2011523937A5 (https=)
JP2017221196A (ja) 免疫調節のための組成物および方法
Yuan et al. Crystalline silica-induced proinflammatory interstitial macrophage recruitment through Notch3 signaling promotes the pathogenesis of silicosis
JP2019518003A5 (https=)
CN102216448A (zh) Foxp3+天然杀伤t细胞及免疫相关疾病的治疗
US20170283769A1 (en) Modified Cells Evoking Reduced Immunogenic Responses
Li et al. “Remodeling the intestinal immune microenvironment”: immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease
Sanati et al. Circular RNAs: key players in tumor immune evasion
RU2012146542A (ru) Способ ингибирования репликации вич в клетках млекопитающих и у людей
Gong et al. Attenuation of experimental autoimmune myocarditis by si-RNA mediated CD40 silencing
Lee et al. Microarray analysis after umbilical cord blood derived mesenchymal stem cells injection in monocrotaline-induced pulmonary artery hypertension rats
Lee et al. Immune Responses Regulated by Exosomal Mechanisms in Cardiovascular Disease
EP4060026A1 (en) Ex-vivo proliferation of human phagocytic cells
Asakura et al. Editor’s Pick 2021: Highlights in Stem Cell Research
MacKerracher The CD8+ memory T cell response following PLGA microparticle immunization